Objective To evaluate the effect of Relugolix combination therapy (Rel-CT) on Quality of Life
(QoL) using the Uterine Fibroid Symptom Health-Related QoL (UFS-QoL) questionnaire, an …

Objective In the pivotal LIBERTY 1 and 2 trials and Long-Term Extension (LTE) study, once-
daily relugolix combination therapy (Rel-CT: relugolix 40 mg, estradiol 1 mg, norethindrone …

Study question What is the effect of relugolix combination therapy (Relugolix-CT) on
symptom burden and health-related quality-of-life (HR-QoL) in patients with uterine fibroids …

Objective To evaluate the time to treatment response with once-daily Relugolix combination
therapy (Rel-CT), assessed by decrease in menstrual blood loss (MBL) volume observed in …

Background Symptomatic uterine fibroids are burdensome to live with; they are associated
with symptom-related distress, affect daily activities, and reduce health-related quality of life …

Objective The Uterine Fibroid Symptom and Quality of Life (UFS-QoL) instrument consists of
6 scales and has been used frequently in clinical trials; the symptom severity scale has 8 …

Objective To evaluate the impact of elagolix, an oral gonadotropin-releasing hormone
antagonist, on the health-related quality of life (HRQL) in women with heavy menstrual …

Objective To investigate the effects of 52 weeks of treatment with relugolix combination
therapy (relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) on symptoms of …

Background In the pivotal LIBERTY 1 and 2 trials and long-term extension study, once-daily
relugolix combination therapy (40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone …

Study question Are symptomatic improvements in women with UF observed after 24 weeks
of linzagolix treatment with or without add-back therapy (ABT) maintained over 52 weeks …